Press Releases

June 15, 2021
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock Read More
June 14, 2021
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock Read More
June 11, 2021
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera Read More
June 7, 2021
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021 Read More
June 3, 2021
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera Read More
May 24, 2021
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 Read More
May 12, 2021
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Read More
May 4, 2021
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update Read More
May 3, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
April 27, 2021
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting Read More
March 22, 2021
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency Read More
March 10, 2021
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Read More
March 3, 2021
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results Read More
March 2, 2021
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference Read More
February 26, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
February 16, 2021
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference Read More
January 29, 2021
Protagonist Therapeutics Reports Granting of Inducement Award Read More
January 4, 2021
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Read More
December 16, 2020
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113) Read More
December 15, 2020
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Read More